Amniocentesis and CVS are prenatal diagnostic procedures. Both can provide more definitive genetic information than screening tests, but they differ in timing, sample type, and when doctors prefer one over the other.
Parents are often offered these procedures after a high-risk NIPT or marker test, increased NT, abnormal ultrasound finding, previous affected pregnancy, or known family genetic condition.
Timing difference
CVS is usually performed earlier, commonly around 11 to 13 weeks depending on local protocol and specialist assessment. Amniocentesis is usually performed from around 15 weeks onward. Timing is one of the main reasons a doctor may recommend one procedure over the other.
Sample difference
CVS samples placental tissue. Amniocentesis samples amniotic fluid containing fetal cells. In most situations, both can answer chromosomal questions, but certain clinical scenarios may favor one sample type.
What tests can be done?
Depending on the indication, samples may be tested using karyotype, FISH, microarray, targeted gene testing, or other advanced genetic tests. The exact test should be chosen before the procedure whenever possible.
Which is safer?
Both are invasive procedures and should be performed by trained specialists under ultrasound guidance. The risk depends on multiple factors including gestational age, placental position, maternal factors, and operator experience. Your fetal medicine specialist should explain procedure-specific risks clearly.
How should parents decide?
Ask what question the test is trying to answer, how quickly results are needed, which test will be performed on the sample, what the possible results mean, and what follow-up is expected.
The decision is personal. A good fetal medicine team helps parents understand choices without pressure and supports them through the testing pathway.